logo
Plus   Neg
Share
Email

Merck KgaA : EU Approves Bavencio To Treat Locally Advanced Or Metastatic Urothelial Carcinoma

EMD Serono, the Healthcare business sector of Merck KgaA (MKGAY.PK), and Pfizer Inc. (PFE) said that the European Commission has approved Bavencio or avelumab as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma or UC who are progression-free following platinum-based chemotherapy.

Bavencio maintenance treatment significantly extended median overall survival versus standard of care in the Phase III JAVELIN Bladder 100 study.

Bavencio was first approved in the US as a first-line maintenance treatment for advanced urothelial carcinoma by the US Food and Drug Administration in June 2020 and is now approved for this indication in 38 countries. Additional regulatory applications are under review in 13 countries, including in Japan, where approval is expected in the first-half 2021.

Bavencio in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma.

Bavencio is currently approved for patients in 50 countries for at least one use.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example. Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations. Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...
Follow RTT